Andrew Wiemer, Ph.D.
Dr. Wiemer is an Assistant Professor in the Department of Pharmaceutical Sciences at the University of Connecticut. He is also affiliated with the Institute for Systems Genomics. Dr. Wiemer received a B.S. in Biology from the University of Notre Dame. He earned a Ph.D. in Molecular & Cellular Biology from the University of Iowa, where he developed novel lipophilic inhibitors of geranylgeranyl diphosphate synthase and other enzymes of isoprenoid biosynthesis. He performed a postdoctoral research at the University of Wisconsin Madison, studying inhibitors of T cell integrin functions and motility stop signals. He has received research support from the National Institutes of Health, the American Cancer Society, the American Association of Colleges of Pharmacy, and the Frasch Foundation for Chemical Research. He is a member of the American Chemical Society, the American Association of Immunologists, the American Society for Pharmacology and Experimental Therapeutics, and the American Association of Colleges of Pharmacy. Dr. Wiemer has served as a grant reviewer for the United States National Science Foundation, the United States Department of Defense, the Israel Ministry of Science, Technology and Space, and the French National Research Agency.
Jin Li, M.S.
Jin Li is a Pharmaceutical Sciences Ph.D. student in Dr. Wiemer’s lab studying Medicinal Chemistry. She received an M.S. in Pharmaceutics and a B.S in Pharmacy from Fudan University, where she did research on development of a targeted gene delivery system for brain cancer therapy. Jin’s research focuses on the discovery of novel therapeutics and immunotherapeutics for malignant tumors.
Sherry Agabiti, B.S.
Sherry Agabiti is a Pharmaceutical Sciences Ph.D. student in the Wiemer lab studying Medicinal Chemistry. She received her undergraduate degree in Physiology & Neurobiology, and English from the University of Connecticut. Sherry’s research focuses on identifying novel compounds for cancer therapy, and investigating the roles of such compounds in cancer cell adhesion, motility, and proliferation.
Megan Schladetsch, B.S.
Megan Schladetsch is a Pharmaceutical Sciences Ph.D. student in the Wiemer lab studying Medicinal Chemistry. She received her B.S. in Biochemistry from the University of Portland in Oregon. Megan’s research currently focuses on testing inhibitors of isoprenoid biosynthesis and their potential effects in the human mevalonate pathway and immunity.
Michael Poe, Ph.D.
Michael Poe is a postdoctoral fellow in Dr. Wiemer’s lab. He received his B.S. in Chemistry from the University of Minnesota-Duluth and his Ph.D. in Organic Chemistry from the University of Wisconsin-Milwaukee, where he synthesized novel GABA agonists. Mike’s research focuses on synthesis and evaluation of novel butyrophilin agonists.